Formulary
Vildagliptin: Indications, Dosing, Side Effects and Interactions
Inhibits dipeptidylpeptidase-4 to increase insulin secretion and lower glucagon secretion.
MedNext Academy | 3 min read
Vildagliptin: Indications, Dosing, Side Effects and Interactions
Inhibits dipeptidylpeptidase-4 to increase insulin secretion and lower glucagon secretion.
Drug action
Inhibits dipeptidylpeptidase-4 to increase insulin secretion and lower glucagon secretion.
Indications and dose
**Type 2 diabetes mellitus as monotherapy (if metformin inappropriate), or in combination with other antidiabetic drugs (including insulin) if existing treatment fails to achieve adequate glycaemic control**
- **Adult** (By Mouth): 50 mg twice daily, reduce dose to 50 mg once daily in the morning when used in dual combination with a sulfonylurea. For further information on use with other antidiabetic drugs-consult product literature.
Cautions
History of pancreatitis; manufacturer advises avoid in severe heart failure-no information available
Side effects
Common or very common Dizziness Uncommon Arthralgia; constipation; headache; hypoglycaemia; peripheral oedema Rare or very rare Increased risk of infection Frequency not known Bullous pemphigoid (discontinue); hepatitis; myalgia; pancreatitis; skin reactions Side-effects, further information Pancreatitis Discontinue if symptoms of acute pancreatitis occur, such as persistent severe abdominal pain. Liver toxicity Rare reports of liver dysfunction; discontinue if jaundice or other signs of liver dysfunction occur.
Interactions
**Other interactions (7):**
- Vildagliptin has a low potential for interactions with co-administered medicinal products.
- Since vildagliptin is not a cytochrome P (CYP) 450 enzyme substrate and does not inhibit or induce CYP 450 enzymes, it is not likely to interact with active substances that are substrates,...
- Combination with pioglitazone, metformin and glyburide Results from studies conducted with these oral antidiabetics have shown no clinically relevant pharmacokinetic interactions.
- Digoxin (Pgp substrate), warfarin (CYP2C9 substrate) Clinical studies performed with healthy subjects have shown no clinically relevant pharmacokinetic interactions.
- Combination with amlodipine, ramipril, valsartan or simvastatin Drug-drug interaction studies in healthy subjects were conducted with amlodipine, ramipril, valsartan and simvastatin.
- In these studies, no clinically relevant pharmacokinetic interactions were observed after co-administration with vildagliptin.
Pregnancy
Avoid-toxicity in animal studies.
Breast feeding
Avoid-present in milk in animal studies.
Hepatic impairment
Manufacturer advises avoid.
Renal impairment
Dose adjustments Reduce dose to 50 mg once daily if creatinine clearance less than 50 mL/minute. M See Prescribing in renal impairment .
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Vildagliptin in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

